Targeting inflammasome-driven neuropathology and motor neuron death in MND using a clinically approved cancer drug. (2020–2022)

Grant type:
Motor Neurone Disease Research Institute of Australia Inc
Researchers:
Funded by:
Motor Neurone Disease Research Institute of Australia Inc